Environmental, Social And Governance Report

Overview

The report describes the Group's 2021 pharmaceutical R&D expansion, including RMB465 million of R&D investment and 23 generic drug and new drug projects under research. It reports 13,368 employees and one work-related death. Community programmes included RMB430,000 in scholarships, while the report also sets out a carbon-neutrality pathway toward 2060.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Language: English
Pages
File size
Restatement: Disclosed

Standards

Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services